



Carbon Reduction Plan

Supplier Name: Rivopharm UK

Publication date: 01/07/2026

Commitment to achieving net zero

Rivopharm UK is committed to achieving net zero emissions by 2045.

Baseline emissions footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year and Current Reporting Year: 2025	
Additional Details relating to the Baseline Emissions calculations.	
Although we have previously measured scope 1, 2 and a subset of scope 3 emissions, in 2025, all relevant scope 3 emissions were included in the measurement due to updated requirements for NHS suppliers. As full scope 3 data was not available for the 2023 base year, and the additional scope 3 emissions were significant, Rivopharm has set a new baseline year of 2025.	
Emissions	Total (tCO2e)
Scope 1	0.0
Scope 2	0.65
Scope 3 (included sources)	2,172.04
3.1 Purchased goods and services	2,096.77
3.2 Capital goods	1.58
3.3 Fuel- and energy-related activities	0.13
3.4 Upstream transportation and distribution	17.34
3.5 Waste generated in operations	0.54



3.6 Business travel	36.44
3.7 Employee commuting	5.67
3.8 Upstream leased assets	Not Relevant
3.9 Transportation and distribution of sold products	0.37
3.10 Processing of sold products	Not Relevant
3.11 Use of sold products	Not Relevant
3.12 End-of-life treatment of sold products	13.21
3.13 Downstream leased assets	Not Relevant
3.14 Franchises	Not Relevant
3.15 Investments	Not Relevant
Total Emissions	2,172.69

Emissions reduction targets

In 2025, Rivopharm UK expanded the scope of its greenhouse gas inventory to include all relevant Scope 3 emissions categories. Previous reporting covered Scope 1, Scope 2 and a subset of Scope 3 emissions, including business travel, employee commuting, waste generated in operations, upstream transportation and distribution, and downstream transportation and distribution. This was sufficient for the previous Carbon Reduction Plan boundary, but does not reflect the full value chain emissions now required for a more complete Scope 3 assessment.

The most significant change in 2025 is the inclusion of a full Purchased Goods and Services calculation. This includes emissions associated with pharmaceutical products and other purchased goods and services. As a result, total reported emissions increased significantly from previous years. This increase should not be interpreted as a like-for-like increase in operational emissions. It is primarily the result of a wider and more complete reporting boundary.

Because full Scope 3 data was not available for the 2023 baseline year, Rivopharm UK has set 2025 as the new baseline year for its updated targets. This provides a more accurate and complete basis for future carbon reduction planning and target tracking.




Rivopharm UK commits to reducing scope 1, 2 and 3 emissions by 42% by 2030 from a 2025 baseline.

Rivopharm UK commits to reducing scope 1, 2 and 3 emissions by 90% by 2045 from a 2025 baseline.

Progress towards these new targets can be seen in the graph below:

Net Zero Targets



Carbon reduction projects

Completed carbon reduction initiatives

Rivopharm UK has made progress in reducing emissions within the previously measured reporting boundary. Emissions within the original subset reduced from approximately 113.83 tCO₂e in 2023 to 61.33 tCO₂e in 2024, before remaining broadly stable at 61.00 tCO₂e in 2025. This represents a significant reduction from the original 2023 baseline boundary.


Progress has been particularly evident in employee commuting and downstream transportation and distribution. Employee commuting emissions reduced from 39.46 tCO₂e in 2023 to 5.67 tCO₂e in 2025, while downstream transportation and distribution reduced from 2.19 tCO₂e to 0.37 tCO₂e over the same period. Scope 2 emissions also reduced from 1.74 tCO₂e in 2023 to 0.65 tCO₂e in 2025.



Rivopharm UK has also continued to monitor and manage emissions from business travel, logistics, waste and office energy use. Previous reduction initiatives included engagement with the landlord on renewable energy and energy efficiency, promotion of virtual meetings, encouragement of lower-carbon travel, support for flexible working, logistics route optimisation, and waste reduction initiatives.

Rivopharm has made progress against the original measured subset of scope 3 emissions as can be seen in the graph below:

Net Zero Targets





Future carbon reduction initiatives

In future reporting periods, Rivopharm UK will focus on reducing emissions across the categories that have the greatest influence on its total footprint. As the 2025 baseline includes all relevant Scope 3 emissions, the company's future reduction strategy will prioritise Purchased Goods and Services, business travel, transportation and distribution, employee commuting, Scope 2 energy use, and end-of-life treatment of sold products.

Key future initiatives include:

- Supplier engagement: engage key pharmaceutical suppliers and other high-impact suppliers to request product-level carbon data, supplier emissions information, and evidence of carbon reduction targets or net zero commitments.
- Sustainable procurement: incorporate carbon considerations into procurement decisions, supplier reviews and contract renewals, prioritising suppliers that can demonstrate credible emissions measurement and reduction plans.
- Pharmaceutical products: work towards improved activity-based and supplier-specific data for pharmaceutical products, as this is the largest source of emissions in the 2025 baseline.
- Business travel: continue to promote virtual meetings where appropriate and maintain travel controls that prioritise lower-carbon travel options, including rail and public transport where practical.
- Logistics and distribution: work with logistics providers to improve shipment-level data, optimise routes, consolidate deliveries where possible, and identify lower-carbon transport options.
- Scope 2 energy: continue engagement with the landlord and energy providers on renewable energy procurement, energy efficiency measures and improved metering.
- Employee commuting: continue to support flexible working, public transport, cycling, walking and other lower-carbon commuting options.
- Waste and end-of-life treatment: improve data collection on packaging, disposal routes and end-of-life treatment of sold products to refine future calculations and identify reduction opportunities.
- Data quality: move progressively from spend-based estimates towards supplier-specific, product-level and activity-based data for the largest emissions categories.



Declaration and sign off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹³ and uses the appropriate government emission conversion factors for greenhouse gas company reporting.¹⁴

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements (where required), and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.¹⁵

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the supplier:

Gareth Evans

Managing Director

Rivopharm UK

Date: 6th July 2026

¹³ <https://ghgprotocol.org/corporate-standard>

¹⁴ www.gov.uk/government/collections/government-conversion-factors-for-company-reporting

¹⁵ <https://ghgprotocol.org/standards/scope-3-standard>